On Tuesday, Standard BioTools Inc (NASDAQ: LAB) opened lower -3.79% from the last session, before settling in for the closing price of $1.32. Price fluctuations for LAB have ranged from $0.92 to $2.14 over the past 52 weeks.
A company in the Healthcare sector has jumped its sales by 11.61% annually for the last half of the decade. Company’s average yearly earnings per share was noted 60.26% at the time writing. With a float of $368.61 million, this company’s outstanding shares have now reached $383.61 million.
Standard BioTools Inc (LAB) Insider Updates
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Standard BioTools Inc is 4.15%, while institutional ownership is 75.45%. The most recent insider transaction that took place on Dec 04 ’25, was worth 217,020. In this transaction Director of this company bought 150,000 shares at a rate of $1.45, taking the stock ownership to the 72,100,000 shares. Before that another transaction happened on Dec 02 ’25, when Company’s Director bought 125,000 for $1.42, making the entire transaction worth $177,512. This insider now owns 71,875,000 shares in total.
Standard BioTools Inc (LAB) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.05 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.03) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.89% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Check out the current performance indicators for Standard BioTools Inc (LAB). In the past quarter, the stock posted a quick ratio of 4.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.45 million. That was inferior than the volume of 1.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.73%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 30.77%, which indicates a significant increase from 8.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0923 in the past 14 days, which was higher than the 0.0787 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3499, while its 200-day Moving Average is $1.2523. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.3217. Second resistance stands at $1.3733. The third major resistance level sits at $1.4167. If the price goes on to break the first support level at $1.2267, it is likely to go to the next support level at $1.1833. Assuming the price breaks the second support level, the third support level stands at $1.1317.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are currently 384,565K shares outstanding in the company with a market cap of 488.40 million. Presently, the company’s annual sales total 174,430 K according to its annual income of -138,890 K. Last quarter, the company’s sales amounted to 19,550 K and its income totaled -34,690 K.
